Flag Therapeutics

Raleigh, United States Founded: 2013 • Age: 13 yrs
Small molecule therapeutics for difficult-to-treat cancers are developed.
Annual revenue - Latest available
Total funding $1.4M 5 rounds
Employees - Tracked headcount
Investors 2 Known backers
Products 2 Services tracked
Competitors - Brand Intelligence

About Flag Therapeutics

Flag Therapeutics is a company based in Raleigh (United States) founded in 2013. Flag Therapeutics has raised $1.37 million across 5 funding rounds from investors including HHS and NCBiotech. Flag Therapeutics offers products and services including FLAG-003 and FLAG-094.

  • Headquarter Raleigh, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Flag Therapeutics, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $1.37 M (USD)

    in 5 rounds

  • Latest Funding Round
    $72.5 K (USD), Seed

    Jun 28, 2019

  • Investors
    HHS

    & 1 more

  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Flag Therapeutics

Flag Therapeutics offers a comprehensive portfolio of products and services, including FLAG-003 and FLAG-094.

Product name locked
Category locked
Primary

Small molecule treatment for DIPG and GBM cancers

Product name locked
Category locked
Locked

Small molecule therapy for endometrial ovarian cancer

Funding Insights of Flag Therapeutics

Flag Therapeutics has successfully raised a total of $1.37M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $72.5 thousand completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Flag Therapeutics

Flag Therapeutics has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS and NCBiotech.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Biotech startups are incubated and funded in North Carolina.
Locked Locked Locked
Public health and human services are overseen by HHS.
Locked Locked Locked
Premium access

Investor details for Flag Therapeutics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Flag Therapeutics

Investments
Premium access

Investment portfolio details for Flag Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Flag Therapeutics

Premium access

Detailed financials for Flag Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Flag Therapeutics Comparisons

Flag Therapeutics Primary company
Description
Small molecule therapeutics for difficult-to-treat cancers a...
Location
Raleigh, United States
Founded Year
2013
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Flag Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Flag Therapeutics

Premium access

Detailed competitors of Flag Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Flag Therapeutics

Premium access

Complete news archive for Flag Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Flag Therapeutics

Flag Therapeutics was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Flag Therapeutics is headquartered in Raleigh, United States. It is registered at Raleigh, North Carolina, United States.

Flag Therapeutics is a funded company, having raised a total of $1.37M across 5 funding rounds to date.

Flag Therapeutics was founded in 2013 in Raleigh, United States, within the biotechnology sector focused on oncology. Small molecule therapeutics are developed using a proprietary platform that produces water-soluble compounds designed to target and bind cancer cells. The pipeline includes FLAG-003, a lead candidate for treating Diffuse Intrinsic Pontine Glioma and glioblastoma multiforme, addressing unmet needs in difficult cancers.

Flag Therapeutics offers FLAG-003 and FLAG-094.

Flag Therapeutics has 2 investors. Key investors include HHS, and NCBiotech.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available